Monte Rosa Therapeutics报告第四季度业绩

2025-03-20 19:44

Monte Rosa Therapeutics press release (NASDAQ:GLUE): Q4 net income was $13.4 million, compared to a net loss of $33.3 million a year ago.
Cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2024, were $377 million vs $247.1 million as of September 30, 2024.
The increase of $129.9 million was primarily related to upfront payment received from Novartis in connection with our license agreement.
Strong cash position expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts.

More on Monte Rosa Therapeutics